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Abstract
A Klebsiella pneumoniae isolate with decreased susceptibility to
carbapenems was isolated in April 2011 in a hospital in Amster-
dam (the Netherlands) and later found to be the source of an
important outbreak in a Rotterdam hospital. The strain, belong-
ing to sequence type (ST) 395, carried the blaOXA-48 gene
located onto a c 62-kb conjugative plasmid, together with the
extended-spectrum b-lactamase gene blaCTX-M-15. It was closely
related or identical to other OXA-48-positive Klebsiella pneumo-
niae isolates belonging to the same ST type and identiﬁed in
France and Morocco. This study sheds light on the European
dissemination of a single OXA-48 K. pneumoniae clone.
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Emergence and dissemination of Enterobacteriaceae isolates
harbouring carbapenem-hydrolysing b-lactamases represent a
signiﬁcant threat to the management of nosocomial and pos-
sibly community-acquired infections [1]. Carbapenem-hydro-
lysing b-lactamases can be of class A (KPC), of class B
(metallo-b-lactamases) or of class D (OXA-48) [1,2]. The
Ambler class D OXA-48 b-lactamase, hydrolyses penicillins
and carbapenems but spares expanded-spectrum cephalospo-
rins. Initially identiﬁed from a carbapenem-resistant K. pneumo-
niae isolate from Turkey [3], outbreaks of OXA-48-producing
Enterobacteriaceae have been described in Turkey [4], France
[5], Tunisia [6], Senegal [7] and now in Spain [8]. There are
additionally scattered reports of OXA-48-producing Entero-
bacteriaceae in several European countries and countries
located in the Mediterranean area such as Lebanon, Belgium,
Egypt, Morocco and Israel [5,9–12]. Here, we report the
ﬁrst OXA-48 producer from the Netherlands and its rela-
tionship with other clonally-related isolates.
In March 2011, a 73-year-old patient was admitted to the
Maasstad Hospital in Rotterdam for a burn wound and inha-
lation trauma. One week after admission, he developed a
blood stream infection involving a multidrug-resistant Klebsiel-
la pneumoniae for which he received 3 g/day (i.v.) of merope-
nem. Five days later, he was transferred from the Maasstad
Hospital in Rotterdam (where a large outbreak has been evi-
denced lately) to the Slotervaart Hospital in Amsterdam. As
he still had a fever (38.9C) upon admission, blood cultures
were performed and identiﬁed the presence of multidrug-
resistant K. pneumoniae with reduced susceptibility to
carbapenems. Meropenem was then switched to intravenous
colistin. Rectal swabs grew the same multidrug-resistant
K. pneumoniae isolate.
The antibiogram determined by the disc diffusion method
and MICs determined by Etest (bioMe´rieux, Marcy l’Etoile,
France) and interpreted according to the CLSI guidelines
[13] revealed that this K. pneumoniae strain AMS was resis-
tant to all penicillins, expanded-spectrum cephalosporins and
to ertapenem (MIC = 2 mg/L), and was susceptible to me-
ropenem (MIC = 0.38 mg/L) and to imipenem (MIC = 0.5
mg/L). That isolate was susceptible to amikacin, tigecycline
(MIC = 0.5 mg/L) and colistin (MIC = 0.5 mg/L) and was
resistant to ﬂuoroquinolones, chloramphenicol, cotrimoxaz-
ole, tetracycline, tobramycin and gentamicin. PCR experi-
ments with primers aimed to detect Ambler class A, class B
and class D carbapenemase genes [14], followed by sequenc-
ing, identiﬁed the carbapenemase blaOXA-48 gene. The
K. pneumoniae AMS isolate also possessed the ESBL gene
blaCTX-M-15 together with the blaOXA-1, blaTEM-1 and blaSHV-1
genes, as reported in many OXA-48 producers [5,7].
The genetic environment of the blaOXA-48 gene was deter-
mined by PCR using speciﬁc primers for the insertion
sequence IS1999, located upstream and downstream of the
blaOXA-48 gene in Tn1999 [15]. A structure similar to
Tn1999, Tn1999.2, was identiﬁed in K. pneumoniae AMS.
Tn1999.2 differs from Tn1999 by the presence of an IS1R
element inserted in the IS1999 element located upstream of
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the blaOXA-48 gene [4]. Mating-out assays and plasmid DNA
analysis performed as described [5,16] allowed the identiﬁca-
tion of the blaOXA-48 gene on a ca 62-kb conjugative plasmid,
although the blaCTX-M-15 gene was identiﬁed on a ca 150-kb
conjugative plasmid. Using speciﬁc primers for the replicase
gene identiﬁed from the ﬁrst reported OXA-48-positive plas-
mid pA1 of Klebsiella pneumoniae 11978 reference strain [3],
namely RepA (5¢-GACATTGAGTCAGTAGAAGG-3¢) and
RepB (5¢-CGTGCAGTTCGTCTTTCGGC-3¢), PCR results
showed that the OXA-48-positive plasmid type identiﬁed in
K. pneumoniae AMS was the same as in K. pneumoniae 11978
and other OXA-48 producers from other geographical ori-
gins (P. Nordmann, personal data).
Multilocus sequence typing (MLST) performed as
described previously [5], showed that K. pneumoniae AMS
displayed ST395 (allelic proﬁle, 3-1-2-4-1-1-4) identical to
that of the K. pneumoniae VSG strain, which was the source
of the only known French outbreak of OXA-48-positive iso-
lates occurring in 2010 in a hospital located in a suburb of
Paris [5], but different from the OXA-48-producing K. pneu-
moniae 11978 from Turkey, which is of ST14 [3]. Moreover,
an ST395 K. pneumoniae strain producing OXA-48 has been
recently identiﬁed in Morocco (P. Nordmann, personal data,
strain A2). The genetic relationship between K. pneumoniae
AMS, K. pneumoniae VSG and K. pneumoniae A2 was studied
using pulsed-ﬁeld gel electrophoresis (PFGE) as described
previously [16] and DiversiLab, a semi-automated typing sys-
tem based on repetitive sequence-based PCR (rep-PCR) fol-
lowing the manufacturer’s instructions (bioMe´rieux). PFGE
and rep-PCR revealed that those three isolates were closely
related, probably corresponding to a single isolate (Fig. 1).
Here we identiﬁed the ﬁrst OXA-48-positive K. pneumo-
niae from the Netherlands. This isolate was closely related
to OXA-48-positive K. pneumoniae isolates from France and
from Morocco. The source of these isolates in the Nether-
lands and in France could not be identiﬁed. It might, how-
ever, be speculated that the OXA-48-positive isolates
identiﬁed in France and the Netherlands may have a relation-
ship with Morocco, where OXA-48 producers are wide-
spread [10,11, P. Nordmann, personal data]. We recently
reported the importation of OXA-48 producers directly
from Morocco to France [10], and also the occurrence of
OXA-48 producers in the environment in Morocco [17].
This study may indicate the likelihood of the large spread of
a single OXA-48 K. pneumoniae clone in the Mediterranean
area and in Europe. This SOS signal highlights the potential
risk of spread of carbapenemase producers as underlined for
NDM-1 producers [18]. It underlines the necessity of sys-
tematic screening of hospitalized patients, resulting from any
international transfer, for multidrug-resistant bacteria.
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